Clinical Radiology
Volume 63, Issue 7 , Pages 756-764 , July 2008

The value of dual time point 18F-FDG PET imaging for the differentiation between malignant and benign lesions

  • X.-L. Lan
    • ,
  • Y.-X. Zhang

      Affiliations

    • Corresponding Author InformationGuarantor and correspondent: Y.-X. Zhang, Department of Nuclear Medicine and PET Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, P.R. China. Tel./fax: +86 27 85726282.
    • ,
  • Z.-J. Wu
    • ,
  • Q. Jia
    • ,
  • H. Wei
    • ,
  • Z.-R. Gao

Received 19 October 2006 ,Revised 5 January 2008 ,Accepted 15 January 2008.

References 

  1. Rohren EM, Turking TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–332
  2. Jarritt PH, Carson KJ, Hounsell AR, et al. The role of PET/CT scanning in radiotherapy planning. Br J Radiol. 2006;79:S27–S35
  3. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996;23:1641–1674
  4. Endo K, Oriuchi N, Higuchi T, et al. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol. 2006;11:286–296
  5. Chang JM, Lee HJ, Goo JM, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol. 2006;7:57–69
  6. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–1417
  7. Liang Y-C, Tang A-W, Xu H. Diagnostic value of (18)F-FDG PET delayed imaging for patients with primary lung cancer. Chin J Nucl Med. 2004;24:27–29[in Chinese]
  8. Kumar R, Loving VA, Chauhan A, et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med. 2005;46:1819–1824
  9. Matthies A, Hickeson M, Cuchiara A, et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871–875
  10. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345–1348
  11. Conrad GR, Sinha P. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun. 2003;4:1129–1137
  12. van Waarde A, Jager PL, Ishiwata K, et al. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47:150–154
  13. Takamochi K, Yoshida J, Murakami K, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer. 2005;47:235–242
  14. Kamel EM, McKee TA, Calcagni ML, et al. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies. Eur J Nucl Med Mol Imaging. 2005;32:641–646
  15. Pauleit D, Zimmermann A, Stoffels G, et al. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med. 2006;47:256–261
  16. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48:35–45
  17. Hashimoto Y, Tsujikawa T, Kondo C, et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med. 2006;47:426–431
  18. Hubner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using “quantitative” parameters of FDG PET images. Chin J Nucl Med. 1996;21:941–949
  19. Kruger S, Buck AK, Blumstein NM, et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med. 2006;260:545–550
  20. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306
  21. Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30
  22. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med. 1994;35:1308–1312

PII: S0009-9260(08)00047-0

doi: 10.1016/j.crad.2008.01.003

Clinical Radiology
Volume 63, Issue 7 , Pages 756-764 , July 2008

Article Tools

* Image Usage & Resolution